Research programme: Clostridium difficile monoclonal antibodies - Biolex

Drug Profile

Research programme: Clostridium difficile monoclonal antibodies - Biolex

Alternative Names: C.difficile research programme - Biolex; Clostridium difficile antibodies research programme - Biolex

Latest Information Update: 19 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biolex
  • Class Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Clostridium infections

Most Recent Events

  • 19 Nov 2010 No development reported - Preclinical for Clostridium infections in USA (unspecified route)
  • 06 May 2004 Epicyte Pharmaceutical has been acquired and merged into Biolex
  • 12 May 2003 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top